The role of Sp1 and Sp3 in the constitutive DPYD gene expression

Biochimica et Biophysica Acta - Gene Structure and Expression

Volumn 1759, Issue 5, 2006, Pages 247-256

  Zhang, Xue ^a   Li, Lin ^b   Fourie, Jeanne ^c   Davie, James R ^b   Guarcello, Vincenzo ^c   Diasio, Robert B ^a,c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

^c University of Alabama at Birmingham   (United States)

Author keywords

Dihydropyrimidine dehydrogenase; DPYD; Promoter; Sp1

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP3;

ARTICLE; BINDING SITE; CANCER CHEMOTHERAPY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENZYME ACTIVITY; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENE FUNCTION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION;

BASE SEQUENCE; BINDING SITES; CELLS, CULTURED; DIHYDROURACIL DEHYDROGENASE (NADP); GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMANS; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS (GENETICS); SP1 TRANSCRIPTION FACTOR; SP3 TRANSCRIPTION FACTOR; TRANS-ACTIVATION (GENETICS);

EID: 33745886277     PISSN: 01674781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbaexp.2006.05.001     Document Type: Article

References (40)

1. Johnston S.J., Ridge S.A., Cassidy J., and McLeod H.L. Regulation of dihydropyrimidine dehydrogenase in colorectal cancer. Clin. Cancer Res. 5 (1999) 2566-2570
2. Johnson M.R., and Diasio R.B. Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. Adv. Enzyme Regul. 41 (2001) 151-157
3. Mattison L.K., Soong R., and Diasio R.B. Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. Pharmacogenomics 3 (2002) 485-492
4. Diasio R.B., and Harris B.E. Clinical pharmacology of 5-fluorouracil. Clin. Pharmacokinet. 16 (1989) 215-237
5. Dobritzsch D., Schneider G., Schnackerz K.D., and Lindqvist Y. Crystal structure of dihydropyrimidine dehydrogenase, a major determinant of the pharmacokinetics of the anti-cancer drug 5-fluorouracil. EMBO J. 20 (2001) 650-660
6. Diasio R.B., and Johnson M.R. Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance. Clin. Cancer Res. 5 (1999) 2672-2673
7. McLeod H.L., Sludden J., Murray G.I., Keenan R.A., Davidson A.I., Park K., Koruth M., and Cassidy J. Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours. Br. J. Cancer 77 (1998) 461-465
8. Van Kuilenburg A.B., Vreken P., Abeling N.G., Bakker H.D., Meinsma R., Van Lenthe H., De Abreu R.A., Smeitink J.A., Kayserili H., Apak M.Y., Christensen E., Holopainen I., Pulkki K., Riva D., Botteon G., Holme E., Tulinius M., Kleijer W.J., Beemer F.A., Duran M., Niezen-Koning K.E., Smit G.P., Jakobs C., Smit L.M., Van Gennip A.H., et al. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum. Genet. 104 (1999) 1-9
9. Queener S.F., Morris H.P., and Weber G. Dihydrouracil dehydrogenase activity in normal, differentiating and regenerating liver and in hepatomas. Cancer Res. 31 (1971) 1004-1009
10. Kashima N., Ueda M., and Kanazawa J. Effect of 5-fluorouracil and epidermal growth factor on cell growth and dihydropyrimidine dehydrogenase regulation in human uterine cervical carcinoma SKG-IIIb cells. Cancer Sci. 94 (2003) 821-825
11. Harris B.E., Song R.L., He Y.J., Soong S.J., and Diasio R.B. Circadian rhythm of rat liver dihydropyrimidine dehydrogenase. Possible relevance to fluoropyrimidine chemotherapy. Biochem. Pharmacol. 37 (1988) 4759-4762
12. Harris B.E., Song R., Soong S.J., and Diasio R.B. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res. 50 (1990) 197-201
13. Collie-Duguid E.S., Johnston S.J., Boyce L., Smith N., Cowieson A., Cassidy J., Murray G.I., and McLeod H.L. Thymidine phosphorylase and dihydropyrimidine dehydrogenase protein expression in colorectal cancer. Int. J. Cancer 94 (2001) 297-301
14. Anan K., Mitsuyama S., Tamae K., Suehara N., Nishihara K., Ogawa Y., Abe Y., Iwashita T., and Toyoshima S. Increased dihydropyrimidine dehydrogenase activity in breast cancer. J. Surg. Oncol. 82 (2003) 174-179
15. Fukushima M., Morita M., Ikeda K., and Nagayama S. Population study of expression of thymidylate synthase and dihydropyrimidine dehydrogenase in patients with solid tumors. Int. J. Mol. Med. 12 (2003) 839-844
16. Nagakawa T., Kayahara M., Ohta T., Kitagawa H., Mikami K., Kurata T., and Otsuji S. Dihydropyrimidine dehydrogenase activity in human pancreatic tumor tissues. Cancer Investig. 18 (2000) 516-520
17. Fujimoto S., Matsuda K., Kikugawa M., Kaneko M., and Tamaki N. Effect of vitamin B2 deficiency on rat liver dihydropyrimidine dehydrogenase activity. J. Nutr. Sci. Vitaminol. (Tokyo) 37 (1991) 89-98
18. Takabayashi A., Iwata S., Kawai Y., Kanai M., Taki Y., Takechi T., and Fukushima M. Dihydropyrimidine dehydrogenase activity and mRNA expression in advanced gastric cancer analyzed in relation to effectiveness of preoperative 5-fluorouracil-based chemotherapy. Int. J. Oncol. 17 (2000) 889-895
19. Fujiwara H., Terashima M., Irinoda T., Takagane A., Abe K., Kashiwaba M., Oyama K., Takahashi M., Maesawa C., Saito K., Takechi T., and Fukushima M. Quantitative measurement of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level in gastric cancer by real-time RT-PCR. Jpn. J. Cancer Res. 93 (2002) 1342-1350
20. Johnson M.R., Wang K., Smith J.B., Heslin M.J., and Diasio R.B. Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. Anal. Biochem. 278 (2000) 175-184
21. Shestopal S.A., Johnson M.R., and Diasio R.B. Molecular cloning and characterization of the human dihydropyrimidine dehydrogenase promoter. Biochim. Biophys. Acta 1494 (2000) 162-169
22. Ukon K., Tanimoto K., Shimokuni T., Noguchi T., Hiyama K., Tsujimoto H., Fukushima M., Toge T., and Nishiyama M. Activator protein accelerates dihydropyrimidine dehydrogenase gene transcription in cancer cells. Cancer Res. 65 (2005) 1055-1062
23. Courey A.J., and Tjian R. Analysis of Sp1 in vivo reveals multiple transcriptional domains, including a novel glutamine-rich activation motif. Cell 55 (1988) 887-898
24. Sapetschnig A., Koch F., Rischitor G., Mennenga T., and Suske G. Complexity of translationally controlled transcription factor Sp3 isoform expression. J. Biol. Chem. 279 (2004) 42095-42105
25. He S., Sun J.M., Li L., and Davie J.R. Differential intranuclear organization of transcription factors sp1 and sp3. Mol. Biol. Cell 16 (2005) 4073-4083
26. Das S., Ward S.V., Tacke R.S., Suske G., and Samuel C.E. Activation of the RNA-dependent protein kinase PKR promoter in the absence of interferon is dependent upon Sp proteins. J. Biol. Chem. 281 6 (2005) 3244-3253
27. Black A.R., Black J.D., and Azizkhan-Clifford J. Sp1 and kruppel-like factor family of transcription factors in cell growth regulation and cancer. J. Cell. Physiol. 188 (2001) 143-160
28. Dishart D., Schnur N., Klan N., Werz O., Steinhilber D., Samuelsson B., and Radmark O. GC-rich sequences in the 5-lipoxygenase gene promoter are required for expression in Mono Mac 6 cells, characterization of a novel Sp1 binding site. Biochim. Biophys. Acta 1738 (2005) 37-47
29. Chalkley G.E., and Verrijzer C.P. DNA binding site selection by RNA polymerase II TAFs: a TAF(II)250-TAF(II)150 complex recognizes the initiator. EMBO J. 18 (1999) 4835-4845
30. Fry C.J., and Farnham P.J. Context-dependent transcriptional regulation. J. Biol. Chem. 274 (1999) 29583-29586
31. Grinstein E., Jundt F., Weinert I., Wernet P., and Royer H.D. Sp1 as G1 cell cycle phase specific transcription factor in epithelial cells. Oncogene 21 (2002) 1485-1492
32. Wei Q., Miskimins W.K., and Miskimins R. The Sp1 family of transcription factors is involved in p27(Kip1)-mediated activation of myelin basic protein gene expression. Mol. Cell. Biol. 23 (2003) 4035-4045
33. Sumi D., and Ignarro L.J. Sp1 transcription factor expression is regulated by estrogen-related receptor alpha1. Biochem. Biophys. Res. Commun. 328 (2005) 165-172
34. Hosoi Y., Watanabe T., Nakagawa K., Matsumoto Y., Enomoto A., Morita A., Nagawa H., and Suzuki N. p-regulation of DNA-dependent protein kinase activity and Sp1 in colorectal cancer. Int. J. Oncol. 25 (2004) 461-468
35. Li L., He S., Sun J.M., and Davie J.R. Gene regulation by Sp1 and Sp3. Biochem. Cell. Biol. 82 (2004) 460-471
36. Qin H., Sun Y., and Benveniste E.N. The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cells. J. Biol. Chem. 274 (1999) 29130-29137
37. Pang R.T., Lee L.T., Ng S.S., Yung W.H., and Chow B.K. CpG methylation and transcription factors Sp1 and Sp3 regulate the expression of the human secretin receptor gene. Mol. Endocrinol. 18 (2004) 471-483
38. Wong W.K., Chen K., and Shih J.C. Decreased methylation and transcription repressor Sp3 up-regulated human monoamine oxidase (MAO) B expression during Caco-2 differentiation. J. Biol. Chem. 278 (2003) 36227-36235
39. Chadjichristos C., Ghayor C., Herrouin J.F., Ala-Kokko L., Suske G., Pujol J.P., and Galera P. Down-regulation of human type II collagen gene expression by transforming growth factor-beta 1 (TGF-beta 1) in articular chondrocytes involves SP3/SP1 ratio. J. Biol. Chem. 277 (2002) 43903-43917
40. Kubota T. 5-fluorouracil and dihydropyrimidine dehydrogenase. Int. J. Clin. Oncol. 8 (2003) 127-131